Uterine fibroids (UF) affect up to 70–80% of women by age 50 and are associated with heavy men- strual bleedings, pelvic discomfort, and reduced quality of life. Uterine artery embolization (UAE) is a minimally invasive procedure that aims to reduce fibroid-related symptoms and improve patients’ quality of life. Materials and methods‒ A prospective single-center study was conducted on 40 women who underwent UAE between November 2018 and June 2023. Primary outcomes were eval- uated using the Uterine Fibroid Symptom and Quality-of- Life (UFS-QoL) questionnaire to assess symptom severity and health-related quality-of-life scores. Secondary out- comes include pain intensity, complications, requirement of additional treatments, and duration of symptoms after discharge. Results‒ Thirty-three patients completed the follow-up UFS-QoL questionnaire. The mean age and the mean follow-up time were 47 years (SD 14 years) and 10 months (SD 4 months), respectively. Substantial improvements were observed within all domains of the UFS-QoL questionnaire (p < 0.001), particularly in symptom severity, where 94% of patients experienced a benefit. All Health Related Quality-of- Life (HRQL) domains statistically significantly improved (73–91%; p < 0.001). 67% of patients did not require further treatments. Pelvic pain, according to VAS, improved by 2.1 (0= much better; 5= no change; 10= worse). Post-procedural complications were minor, 70% of patients reported symp- toms persisted up to 5 days after discharge, and 88% resolved within 2 weeks. Despite a 45.5% rate of minor complications, including pain and transitory bleeding, 88% of patients would recommend UAE, underlining its safety and effectiveness. Discussion and conclusion‒ UAE offers substantial bene- fits for symptomatic fibroids, significantly improving HRQoL, symptom severity and pelvic pain scores, making it a valuable alternative to surgery. Complications were minor and short- lived, and the majority of patients were satisfied with the results, with no need for additional treatments. Further research is warranted to generate peri-procedural pain man- agement consensus guidelines, clinical outcomes of radial access, and fertility-related outcomes.
Uterine fibroid embolization: an analysis of clinical outcomes and impact on patients' quality of life / Ubaldi, N.; Andrea Tipaldi, M.; Giannini, A.; Golia D'Augè, T.; Caserta, D.; Simone Laganà, A.; Grasso, G.; Zolovkins, A.; Ronconi, E.; Rossi, M.. - In: OPEN MEDICINE. - ISSN 2391-5463. - 20:1(2025), pp. 1-9. [10.1515/med-2025-1235]
Uterine fibroid embolization: an analysis of clinical outcomes and impact on patients' quality of life
Andrea Tipaldi M.;Giannini A.;Ronconi E.;
2025
Abstract
Uterine fibroids (UF) affect up to 70–80% of women by age 50 and are associated with heavy men- strual bleedings, pelvic discomfort, and reduced quality of life. Uterine artery embolization (UAE) is a minimally invasive procedure that aims to reduce fibroid-related symptoms and improve patients’ quality of life. Materials and methods‒ A prospective single-center study was conducted on 40 women who underwent UAE between November 2018 and June 2023. Primary outcomes were eval- uated using the Uterine Fibroid Symptom and Quality-of- Life (UFS-QoL) questionnaire to assess symptom severity and health-related quality-of-life scores. Secondary out- comes include pain intensity, complications, requirement of additional treatments, and duration of symptoms after discharge. Results‒ Thirty-three patients completed the follow-up UFS-QoL questionnaire. The mean age and the mean follow-up time were 47 years (SD 14 years) and 10 months (SD 4 months), respectively. Substantial improvements were observed within all domains of the UFS-QoL questionnaire (p < 0.001), particularly in symptom severity, where 94% of patients experienced a benefit. All Health Related Quality-of- Life (HRQL) domains statistically significantly improved (73–91%; p < 0.001). 67% of patients did not require further treatments. Pelvic pain, according to VAS, improved by 2.1 (0= much better; 5= no change; 10= worse). Post-procedural complications were minor, 70% of patients reported symp- toms persisted up to 5 days after discharge, and 88% resolved within 2 weeks. Despite a 45.5% rate of minor complications, including pain and transitory bleeding, 88% of patients would recommend UAE, underlining its safety and effectiveness. Discussion and conclusion‒ UAE offers substantial bene- fits for symptomatic fibroids, significantly improving HRQoL, symptom severity and pelvic pain scores, making it a valuable alternative to surgery. Complications were minor and short- lived, and the majority of patients were satisfied with the results, with no need for additional treatments. Further research is warranted to generate peri-procedural pain man- agement consensus guidelines, clinical outcomes of radial access, and fertility-related outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ubaldi_Uterine_2025.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
940.85 kB
Formato
Adobe PDF
|
940.85 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


